Philippe Chambon, M.D., Ph.D.
Phillipe Chambon, is a Managing Director and founder of New Leaf Venture Partners, LLC (NLV Partners). NLV Partners recently came about with the spin-off of the healthcare team from The Sprout Group. Prior to NLV, Philippe was a General Partner at Sprout which he joined in 1995. He has been a founding investor in five companies, and led multiple later stage investments and one buy-out. He is an active investor in all three sectors of interest for NLV. In addition to serving on VaxInnate's board of directors, Philippe serves on the boards of directors of Artisan Pharma, Auxilium Pharmaceuticals, Aureon Biosciences, BioRelix, ePocrates and NxStage Medical. His prior investments include Cephalon, Focus Technologies, Sapient Health Network (WebMD), Charles River Laboratories and Combichem. Immediately prior to joining Sprout, Philippe was a Manager in the healthcare practice of the Boston Consulting Group. Previously, Philippe was an executive with Sandoz Pharmaceutical for seven years, where he built and led an organization responsible for late stage clinical project management, portfolio management, and pre-marketing activities. He conducted graduate research in molecular immunology at The Pasteur Institute. He earned an MD and PhD from the University of Paris, and an MBA from Columbia University.
Thomas
Hofstaetter, Ph.D.
Prior to
joining
VaxInnate,
Dr.
Hofstaetter
spent more
than 30
years in
leadership
positions at
research-based
pharmaceutical
companies.
He held
executive
roles in
research and
development,
as well as
strategy and
business
development,
during
postings
around the
world,
including
the United
States,
Japan,
France and
his native
Germany.
During his
service at
Wyeth from
2004 until
the firm’s
acquisition
by Pfizer in
2009, Dr.
Hofstaetter
was Senior
Vice
President of
Corporate
Business
Development
and a member
of both the
Wyeth
Management
Committee,
and the
Pharmaceuticals
Management
Team. A
biochemist
by training,
Dr.
Hofstaetter
holds a PhD
in Molecular
Biology,
magna cum
laude, and a
Master of
Science
degree in
Biochemistry
from the
University
of Tuebingen
in Germany.
Dr.
Hofstaetter
began his
pharmaceutical
industry
career in
1978, when
he joined
Behringwerke
AG in
Marburg,
Germany, as
a research
scientist,
rising to
become Head
of Research
and later
General
Manager of
the Business
Unit for
Immunology
and
Oncology.
From 1991
through 1994
he served as
General
Manager of
the
Pharmaceuticals
Unit of
Hoechst
Japan in
Tokyo. He
moved to the
United
States in
1995 to
become
Senior Vice
President of
Business
Development
and Strategy
for Hoechst
Marion
Roussel.
From 1999 to
2004, Dr.
Hofstaetter
was Senior
Vice
President of
Corporate
Development
at Aventis.
Augustine Lawlor
Gus Lawlor is the Managing Partner of HealthCare Ventures LLC. He has over twenty years operating experience in the health care biotechnology industry in finance, business development, mergers and acquisitions, and general management. Before joining HelathCare Ventures, Gus was Chief Operating Officer of LeukoSite, Inc. Prior to LeukoSite, he was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technology. He was previously Chief Financial Officer and Vice President of Business Development of BioSurface Technology. Gus serves on the Boards of Directors of Catalyst Biosciences, in S. San Francisco, CA; Dynogen Pharmaceuticals, in Boston, MA; FoldRx Pharmaceuticals, Inc., in Cambridge, MA; GlobeImmune, Inc., in Aurora CO; Human Genome Sciences, Inc., in Rockville, MD; Promedior, Inc., in Malvern, PA; Replidyne, Inc., in Louisville, CO; Synovex Corporation, in Cambridge, MA; U.S. Genomics, in Woburn, MA; and the Slater Center in Providence, RI. He received a Master's Degree in Management from Yale University.
Seth Rudnick, M.D.
Seth Rudnick joined Canaan in 1998 as a Venture Partner focusing on healthcare investments. He became a General Partner in 2000. His background in the healthcare industry includes comprehensive experience in research, development, clinical trials analysis and biotechnology, as well as founding and growing start-up companies in the industry. Seth currently sits on the boards of Adlyfe, Orthocon, Sopherion, and Spine Wave. Prior to joining Canaan, Seth served as CEO and Chairman at CytoTherapeutics (CTII). Before that, he helped start and served as head of R&D for Ortho Biotech, a division of Johnson & Johnson. In that role, he led the development efforts for a portfolio of projects which are still responsible for significant Johnson and Johnson revenues. He began his industrial career at Schering-Plough where he ran clinical trials for the alpha interferon project, and later transferred to Biogen to run that company's pharmaceutical development efforts. His academic career began when he served on the medical and public health faculty at Chapel Hill. Seth is a Clinical Professor of Medicine at Chapel Hill where he teaches and advises the faculty on biotechnology issues. Recently, Seth was included in the 2006 Midas List, a prominent venture capital listing which ranks the best dealmakers in high-tech and life sciences.
Alan Shaw, Ph.D.
Dr. Shaw joined VaxInnate from the Merck Vaccine Research Division where he was Executive Director of MVD's Public Policy, Public Health and Medical Affairs Department. Prior to this, he was the Executive Director of Virus & Cell Biology at Merck Research Laboratories, responsible for all the aspects of live virus vaccine research, as well as technical aspects of development and production. His responsibilities covered research and early development of recombinant protein-based vaccines. Dr. Shaw was instrumental in the development of a combination measles-mumps-rubella-varicell vaccine (ProQuad®), a live oral rotavirus vaccine, (RotaTeq®), human papillomavirus vaccine (Gardasil®), and the candidate zoster vaccine (Zostavax®) as well as numerous early-stage experimental vaccines. He has over 15 years of experience in the development, testing manufacturing, and implementation of vaccines in the United States, Europe and in international programs. Prior to joining Merck, Dr. Shaw worked on vaccines for hepatitis B and Plasmodium falciparum as well as cytokines, cell trafficking and natural inhibitors of inteleukin-1 at Biogen, SA in Geneva, Switzerland.
David J. Williams
David J.
Williams, is the
retired Chairman
& CEO of sanofi
pasteur, the
vaccines
business of
sanofi-aventis
Group. His 30
year tenure with
the company was
marked by his
rise from
Finance Manager
to President and
CEO. His
leadership moved
the company from
a niche vaccine
business to the
global leader in
vaccine
development,
production and
sales. In
addition, he was
Chairman of the
company’s board
of directors and
a Co-Chair of
the Supervisory
Board of Sanofi
Pasteur MSD, a
50-50 joint
venture with
Merck & Co. that
markets and
distributes
vaccines in
Europe. Prior
to sanofi, Mr.
Williams spent
more than five
years at
Pricewaterhouse
Coopers in their
Audit and
Healthcare
Consulting
Group. Mr.
Williams served
on the Board of
Directors of the
Biotechnology
Industry
Organization
(BIO), AllOne
Health Group,
Xcellerex , Blue
Cross of
Northeastern
Pennsylvania and
the Hospital
Service
Association of
Northeastern
Pennsylvania.
For many years,
he has been
affiliated with
the University
of Scranton,
from which he
has his
undergraduate
degree, is a
past member of
the Board of
Trustees and
Board of
Regents. He is
also one of the
founding Board
Members of the
Medical
Education
Development
Consortium,
which is
creating the
first and only
medical college
in Northeastern
Pennsylvania.
Mr. Williams is
spending his
retirement
serving as a
consultant to
several vaccine
and biotech
companies.
Samuel Wu,
M.D. Ph.D
Before joining
MedImmune
Ventures in
2010, Sam was a
principal at SV
Life Sciences
for eight years,
where he
invested in and
worked with a
broad range of
biopharmaceutical,
platform and
medical device
companies.
Previously, he
was an
Engagement
Manager with
McKinsey and
Company's
Pharmaceuticals
and Medical
Products
practice, where
he led teams of
consultants
serving clients
on M&A,
portfolio
analysis and
other strategic
issues. Sam
holds an A.B.
magna cum laude
in Biochemistry
from Harvard
College,
attended
Stanford
University
School of
Medicine where
he earned an
M.D. and a Ph.D.
in Biochemistry
as a Howard
Hughes
Predoctoral
Fellow, and
trained in
Internal
Medicine at the
University of
California, Los
Angeles.
|
